cyc 202 has been researched along with harmol in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (harmol) | Trials (harmol) | Recent Studies (post-2010) (harmol) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 83 | 1 | 16 |
| Protein | Taxonomy | cyc 202 (IC50) | harmol (IC50) |
|---|---|---|---|
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | 44.91 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.09 | |
| Serine/threonine-protein kinase haspin | Homo sapiens (human) | 0.77 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Y; Duan, J; Kesuma, D; Qi, RZ; Sim, MM; Song, Y; Teng, SF; Wang, J; Wang, JH | 1 |
| Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M | 1 |
1 review(s) available for cyc 202 and harmol
| Article | Year |
|---|---|
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2018 |
1 other study(ies) available for cyc 202 and harmol
| Article | Year |
|---|---|
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
Topics: Carbolines; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Protein Serine-Threonine Kinases | 2002 |